Integrating Clinical and Histopathological Data to Predict Delayed Graft Function in Kidney Transplant Recipients Using Machine Learning Techniques.

Given the significant impact of delayed graft function (DGF) on transplant outcomes, the aim of this study was to develop and validate machine learning (ML) models capable of predicting the risk of DGF in deceased-donor kidney transplantation (DDKT). This retrospective cohort study was conducted using clinical and histopathological data collected between 2018 and 2022 at Ramathibodi Hospital from DDKT donors, recipients, and post-implantation time-zero kidney biopsy samples to develop predictive models. The performance of three ML models (neural network, random forest, and extreme gradient boosting [XGBoost]) and traditional logistic regression on an independent test data set was evaluated using the area under the receiver operating characteristic curve (AUROC) and Brier score calibration.

Impact of donor-specific antibody with low mean fluorescence intensity on allograft outcomes in kidney transplant.

Background: Immune-mediated rejection is the most common cause of allograft failure in kidney transplant (KT) patients. Exposure to alloantigen, including human leukocyte antigen (HLA), results in the production of donor-specific antibodies (DSA). There are limited data about low levels of mean fluorescence intensity (MFI) DSA, especially post-transplantation.

The Effect of a Booster Dose mRNA Vaccine on COVID-19 Infection in Kidney Transplant Recipients after Inactivated or Viral Vector Vaccine Immunization.

The mortality rate after novel coronavirus infection, which causes severe acute respiratory distress syndrome (SARS-CoV-2), is much higher in kidney transplant recipients (KTRs) compared to the general population. Seroconversion after vaccination is also lower, and breakthrough infection is much higher. Many studies reported seroconversion rate after a booster (third) dose of vaccine but clinical outcomes received less attention.

Expanded Criteria Donor With Severe Acute Kidney Injury: Worth to Use?

Background: Expanded criteria donors (ECDs) may present with acute kidney injury (AKI). Many transplantation centers refuse to use these kidneys because of concerns about poor transplant outcomes, resulting in a high discard rate. However, long-term results of ECDs with AKI (ECDs + AKI) have not been extensively studied.

Benefits of Inactivated Vaccine and Viral Vector Vaccine Immunization on COVID-19 Infection in Kidney Transplant Recipients.

The coronavirus virus disease 2019 (COVID-19) pandemic has impacted the global healthcare system. In Thailand, the first and most available vaccines were inactivated and viral vector vaccines. We reported the impact of those vaccines in preventing severe disease and death in kidney transplant recipients.

Trough Level and Tacrolimus Variability of Early Converted Once-Daily Tacrolimus: 1-Year Follow-up Study.

Introduction: Long-term transplant outcomes are considered a crucial point for kidney transplantation. Follow-up studies in patients receiving early conversion to once-daily tacrolimus (TAC-OD) are still limited. We aimed to investigate tacrolimus trough level (C), intrapatient variability of tacrolimus dose-normalized C (TAC-C/D), along with other outcomes between twice-daily tacrolimus (TAC-BID) and early converted TAC-OD.

Stabilization of estimated glomerular filtration rate in kidney transplantation from deceased donors with acute kidney injuries.

Aim: To evaluate and compare the outcomes of kidney transplant (KT) from deceased donors among standard criteria, acute kidney injury (AKI) and expanded criteria donors (ECDs).

Methods: This retrospective study included 111 deceased donor kidney transplant recipients (DDKT). Deceased donors were classified as standard criteria donor (SCD), AKI donor and ECD.